Your browser is no longer supported. Please, upgrade your browser.
Settings
CATB Catabasis Pharmaceuticals, Inc. daily Stock Chart
CATB [NASD]
Catabasis Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.03 Insider Own4.20% Shs Outstand71.23M Perf Week-3.27%
Market Cap46.30M Forward P/E- EPS next Y-0.56 Insider Trans0.00% Shs Float68.05M Perf Month-13.52%
Income-26.60M PEG- EPS next Q-0.14 Inst Own52.20% Short Float0.57% Perf Quarter-59.88%
Sales0.50M P/S92.60 EPS this Y43.20% Inst Trans248.21% Short Ratio0.45 Perf Half Y-59.38%
Book/sh1.40 P/B0.46 EPS next Y17.60% ROA-96.60% Target Price3.83 Perf Year-46.28%
Cash/sh- P/C- EPS next 5Y- ROE-123.70% 52W Range0.61 - 3.78 Perf YTD-56.38%
Dividend- P/FCF- EPS past 5Y-2.20% ROI-189.50% 52W High-83.20% Beta-
Dividend %- Quick Ratio10.20 Sales past 5Y- Gross Margin- 52W Low4.11% ATR0.06
Employees38 Current Ratio10.20 Sales Q/Q- Oper. Margin- RSI (14)37.52 Volatility5.30% 8.96%
OptionableNo Debt/Eq0.02 EPS Q/Q38.10% Profit Margin- Rel Volume0.48 Prev Close0.65
ShortableYes LT Debt/Eq0.00 EarningsAug 09 BMO Payout- Avg Volume859.74K Price0.64
Recom1.00 SMA20-5.16% SMA50-26.11% SMA200-57.08% Volume171,669 Change-2.29%
Oct-05-17Reiterated Oppenheimer Outperform $4 → $7
Feb-02-17Downgrade Citigroup Buy → Neutral
Dec-22-16Initiated H.C. Wainwright Buy $14
Jun-08-16Reiterated Wedbush Outperform $27 → $17
Jul-20-15Initiated Wedbush Outperform $27
Jul-20-15Initiated Oppenheimer Outperform $28
Jul-20-15Initiated Citigroup Buy $21
Aug-09-18 09:48AM  Catabasis Pharmaceuticals: 2Q Earnings Snapshot Associated Press
08:05AM  Catabasis Pharmaceuticals Reports Second Quarter 2018 Financial Results and Reviews Business Progress Business Wire
06:30AM  Catabasis Pharmaceuticals Inc to Host Earnings Call ACCESSWIRE
Aug-08-18 08:00AM  Catabasis Pharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference Business Wire +9.16%
Jul-26-18 08:00AM  Free Technical Insights on BioPharmX and Three Other Biotech Stocks ACCESSWIRE +6.01%
08:00AM  Catabasis Pharmaceuticals to Report Second Quarter 2018 Financial Results and Recent Corporate Developments on Thursday, August 9 Business Wire
Jul-09-18 08:00AM  Catabasis Pharmaceuticals Announces Plans for Edasalonexent Phase 3 POLARIS DMD Trial in Duchenne Muscular Dystrophy Business Wire
Jun-26-18 07:45AM  Analysis: Positioning to Benefit within The Manitowoc, Omeros, Catabasis Pharmaceuticals, Zayo Group, Covanta Holding, and Seattle Genetics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jun-25-18 03:40PM  Catabasis Pharmaceuticals Presents New Edasalonexent Clinical Biomarker Data Showing NF-kB Inhibition and Target Engagement in the MoveDMD® Trial Business Wire
08:30AM  Catabasis Pharmaceuticals, Edasalonexent for the Treatment of Duchenne Muscular Dystrophy Showing Early Clinical Success ACCESSWIRE
Jun-22-18 04:05PM  Catabasis Pharmaceuticals Announces Closing of $42M Underwritten Public Offering Business Wire
Jun-20-18 09:10AM  Catabasis Pharmaceuticals Announces Pricing of $42 Million Underwritten Public Offering Business Wire -14.71%
Jun-18-18 08:00AM  Catabasis Pharmaceuticals to Present at Upcoming Scientific and Advocacy Conferences Business Wire -20.90%
Jun-06-18 12:58PM  Catabasis Pharmaceuticals Incs (NASDAQ:CATB) Path To Profitability Simply Wall St.
May-11-18 05:09PM  Keryx (KERX) Loss Narrower than Expected in Q1, Sales Beat Zacks
02:41PM  Edited Transcript of CATB earnings conference call or presentation 10-May-18 12:30pm GMT Thomson Reuters StreetEvents
09:42AM  Intrexon (XON) Q1 Loss Narrower Than Expected, Revenues Miss Zacks
05:59AM  Endocyte (ECYT) Q1 Loss Narrower Than Expected, Shares Up Zacks
May-10-18 12:35PM  Catalyst (CPRX) Posts In-Line Q1 Loss, Pipeline Progresses Zacks -8.94%
09:12AM  Catabasis Pharmaceuticals: 1Q Earnings Snapshot Associated Press
08:05AM  Catabasis Pharmaceuticals Reports First Quarter 2018 Financial Results and Reviews Business Progress Business Wire
May-09-18 10:35AM  Does Catabasis Pharmaceuticals Incs (NASDAQ:CATB) Past Performance Indicate A Stronger Future? Simply Wall St. +7.19%
08:15AM  Market Trends Toward New Normal in Church & Dwight Co., Rent-A-Center, Teradata, Catabasis Pharmaceuticals, Tronox, and Callaway Golf Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
May-04-18 02:17PM  AMAG Pharma (AMAG) Q1 Loss Wider Than Expected, Lifts View Zacks
11:24AM  Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Impress Zacks
May-03-18 08:00AM  Catabasis Pharmaceuticals to Report First Quarter 2018 Financial Results and Recent Corporate Developments on Thursday, May 10 Business Wire
May-02-18 10:59AM  Novo Nordisk (NVO) Beats Q1 Earnings Estimates, Sales Miss Zacks
10:49AM  Zoetis (ZTS) Beats on Q1 Earnings & Sales, Retains '18 View Zacks
Apr-26-18 10:09AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
08:07AM  Benzinga's Daily Biotech Pulse: Catabasis Soars On Trial Results, Eloxx Listing, Biomarin Earnings Benzinga
Apr-25-18 05:00PM  Catabasis Pharmaceuticals Presents New Edasalonexent Data Showing Significantly Slowed Duchenne Muscular Dystrophy Disease Progression as Measured by MRI Through One Year of Treatment Business Wire
07:59AM  Catabasis Pharmaceuticals, Inc. (CATB) Sees Hammer Chart Pattern: Time to Buy? Zacks
Apr-18-18 08:00AM  Catabasis Pharmaceuticals to Present Results from the MoveDMD® Trial of Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 70th Annual Meeting Business Wire
Apr-17-18 06:35PM  Alnylam (ALNY) Reports Positive Data for RNAi Candidate Zacks
06:33PM  Alkermes Rallies as FDA Accepts NDA for Depression Drug Zacks
04:01PM  Catabasis Pharmaceuticals Aligns Resources to Focus on Lead Program Edasalonexent for the Treatment of Duchenne Muscular Dystrophy Business Wire
Apr-13-18 11:13AM  Here's Why Geron Stock Surged More Than 90% in 6 Months Zacks
Apr-12-18 11:37AM  FDA Lifts Clinical Hold on Bellicum's (BLCM) T Cell Therapy Zacks
Apr-11-18 04:11PM  Epizyme (EPZM) Publishes Tazemetostat Phase I Data, Stock Up Zacks
09:36AM  Spectrum Pharma Stock Up on Positive Lung Cancer Study Data Zacks
Mar-23-18 07:00AM  Wired News FDA Permitted a Single Registration Trial Assessing Eiger BioPharmas Lonafarnib in HDV to Support NDA Filing ACCESSWIRE -5.42%
Mar-19-18 12:12PM  Edited Transcript of CATB earnings conference call or presentation 15-Mar-18 8:30pm GMT Thomson Reuters StreetEvents
Mar-15-18 05:39PM  Catabasis Pharmaceuticals posts 4Q loss Associated Press
04:10PM  Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Reviews Business Progress Business Wire
12:15PM  Catabasis Pharmaceuticals Inc to Host Earnings Call ACCESSWIRE
Mar-11-18 01:19PM  Catella Strengthens UK Presence by Signing a Conditioned Share Purchase Agreement to Acquire Majority Stake in APAM Ltd PR Newswire
Mar-08-18 08:00AM  Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Recent Corporate Developments on Thursday, March 15 Business Wire
Mar-07-18 08:15AM  Detailed Research: Economic Perspectives on RPC, Catabasis Pharmaceuticals, Zayo Group, Catalent, ARRIS International, and McCormick & Company What Drives Growth in Today's Competitive Landscape GlobeNewswire
Mar-02-18 08:30AM  Todays Research Reports on Trending Tickers: Catabasis Pharmaceuticals and Synergy Pharmaceuticals ACCESSWIRE
Feb-14-18 08:30AM  Todays Research Reports on Trending Tickers: Catabasis Pharmaceuticals and ImmunoCellular Therapeutics ACCESSWIRE -10.90%
Feb-13-18 08:00AM  Catabasis Pharmaceuticals Reports Edasalonexent Preserved Muscle Function and Substantially Slowed Duchenne Muscular Dystrophy Disease Progression Through More Than One Year of Treatment Business Wire +24.80%
Jan-09-18 10:42AM  Amgen Announces Acceptance of MAA for Evenity in Europe Zacks
Jan-08-18 05:54PM  Ultragenyx Announces Interim Data from Early Stage Study Zacks
Dec-06-17 02:01AM  Summit, Santhera, Catabasis and Duchenne UK to Host DMD Awareness Day GlobeNewswire
02:00AM  Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne Muscular Dystrophy Awareness Day GlobeNewswire
01:01AM  Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne Muscular Dystrophy Awareness Day GlobeNewswire
Nov-21-17 08:00AM  Catabasis Pharmaceuticals to Present at 29th Annual Piper Jaffray Healthcare Conference Business Wire
Nov-14-17 04:32PM  Edited Transcript of CATB earnings conference call or presentation 9-Nov-17 9:30pm GMT Thomson Reuters StreetEvents -5.88%
Nov-13-17 08:20AM  Analysis: Positioning to Benefit within Catabasis, Flowserve, MGIC Investment, Arrowhead, Silver Spring, and Live Nation Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire -6.59%
Nov-09-17 04:17PM  Catabasis Pharmaceuticals posts 3Q loss Associated Press
04:10PM  Catabasis Pharmaceuticals Reports Third Quarter 2017 Financial Results and Reviews Business Progress Business Wire
11:55AM  Is Catabasis Pharmaceuticals Inc (CATB) A Financially Sound Company? Simply Wall St.
10:10AM  Catabasis Pharmaceuticals Inc to Host Earnings Call ACCESSWIRE
Nov-02-17 08:00AM  Catabasis Pharmaceuticals to Report Third Quarter 2017 Financial Results and Recent Corporate Developments on Thursday, November 9 Business Wire -6.12%
Oct-26-17 08:00AM  Catabasis Pharmaceuticals Announces Upcoming Presentation on CAT-5571 as a Potential Treatment for Cystic Fibrosis at the 31st Annual North American Cystic Fibrosis Conference Business Wire
Oct-06-17 07:30AM  Corporate News Blog - Catabasis Pharma Shares Positive Results from Phase-2 MoveDMD Trials for Assessing Edasalonexent for Treatment of Duchenne Muscular Dystrophy ACCESSWIRE -12.32%
Oct-05-17 11:47AM  Catabasis' DMD Candidate Slows Disease Progression, Stock Up Zacks -6.27%
08:00AM  Today's Research Reports on Trending Tickers: Catabasis Pharmaceuticals and Momenta Pharmaceuticals ACCESSWIRE
Oct-04-17 12:38PM  Evidence of Biotech Froth Continues to Mount Bloomberg +7.07%
08:30AM  Catabasis Pharmaceuticals (CATB) Surges: Stock Moves 7.2% Higher Zacks
07:44AM  Catabasis's stock rockets after positive trial results of Duchenne muscular dystrophy treatment MarketWatch
04:55AM  Armed with fresh trial data, Catabasis doubles down on Duchenne drug American City Business Journals
04:30AM  Catabasis Pharmaceuticals Reports Positive Results from Open-Label Extension of Phase 2 MoveDMD® Trial Evaluating Edasalonexent in Duchenne Muscular Dystrophy and Plans to Initiate Phase 3 Clinical Trial in First Half 2018 Business Wire
Oct-03-17 08:10AM  Today's Research Reports on Stocks to Watch: Catabasis Pharmaceuticals and Rigel Pharmaceuticals ACCESSWIRE +7.20%
Sep-28-17 08:30AM  Catabasis Pharmaceuticals to Present Results from Joint Research Collaboration with Sarepta Therapeutics at the 22nd International Congress of the World Muscle Society Business Wire +21.86%
Sep-27-17 01:47AM  Catella: European Residential Properties Show Large Potential for Appreciation PR Newswire
Sep-14-17 08:00AM  Catabasis Pharmaceuticals to Present Results from the Open-Label Extension of the MoveDMD® Phase 2 Trial of Edasalonexent in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society Business Wire +15.86%
Sep-11-17 10:58AM  Top Ranked Momentum Stocks to Buy for September 11th Zacks
Aug-29-17 07:46AM  Catella AB's Comments on Nasdaq Stockholm's Trading Halt for the Company's Class A-Shares PR Newswire +5.34%
Aug-16-17 03:48AM  Edited Transcript of CATB earnings conference call or presentation 10-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-10-17 09:37PM  Catabasis Pharmaceuticals posts 2Q loss Associated Press
04:10PM  Catabasis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Reviews Business Progress Business Wire
03:00PM  Investor Network: Catabasis Pharmaceuticals Inc to Host Earnings Call ACCESSWIRE
Aug-09-17 08:00AM  Catabasis Pharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference Business Wire
Jul-27-17 08:00AM  Catabasis Pharmaceuticals to Report Second Quarter 2017 Financial Results and Recent Corporate Developments on Thursday, August 10 Business Wire
Jun-23-17 08:00AM  Catabasis Pharmaceuticals to Present Results from the MoveDMD® Trial of Edasalonexent (CAT-1004) at the 2017 PPMD Annual Connect Conference Business Wire
Jun-08-17 11:00AM  Catabasis Pharmaceuticals Presents New Data for CAT-5571 as a Novel Potential Oral Treatment for Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference Business Wire
Jun-02-17 08:00AM  Catabasis Pharmaceuticals to Present CAT-5571, a Novel Activator of Autophagy, as a Potential Treatment for Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference Business Wire
May-18-17 10:23AM  J&J (JNJ) Plans to Seek Approval for 10 New Drugs by 2021 Zacks
May-17-17 03:53PM  Edited Transcript of CATB earnings conference call or presentation 11-May-17 8:30pm GMT Thomson Reuters StreetEvents
10:07AM  Orexigen (OREX) Obesity Drug Contrave Registers Slow Growth Zacks
May-12-17 11:34AM  Edited Transcript of CATB earnings conference call or presentation 11-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-11-17 04:14PM  Catabasis Pharmaceuticals posts 1Q loss Associated Press
04:10PM  Catabasis Pharmaceuticals Reports First Quarter 2017 Financial Results and Reviews Business Progress Business Wire
03:00PM  Investor Network: Catabasis Pharmaceuticals Inc to Host Earnings Call Accesswire
Apr-27-17 08:00AM  Catabasis Pharmaceuticals to Report First Quarter 2017 Financial Results and Recent Corporate Developments on Thursday, May 11 Business Wire
Apr-25-17 08:00AM  Catabasis Pharmaceuticals Announces Favorable Results for Functional Assessments in the MoveDMD® Trial for Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 69th Annual Meeting Business Wire
Apr-18-17 08:00AM  Catabasis Pharmaceuticals to Present at the American Academy of Neurology 69th Annual Meeting Business Wire +10.20%
Mar-23-17 01:04PM  CATABASIS PHARMACEUTICALS INC Financials -6.05%
Mar-17-17 01:48PM  Edited Transcript of CATB earnings conference call or presentation 16-Mar-17 8:30pm GMT Thomson Reuters StreetEvents -8.82%
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule, which completed Phase II clinical trial for the treatment of duchenne muscular dystrophy (DMD), as well as Phase I clinical trial for the treatment of additional rare diseases. It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) and malfunctioning of CF transmembrane conductance regulator, as well as for the clearance of pathogens, such as P. aeruginosa and B. cenocepacia; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases consisting of Friedreich's ataxia and amyotrophic lateral sclerosis. In addition, the company offers CAT-2000 compounds, which are SMART linker conjugates of nicotinic acid and EPA that are used for the treatment of nonalcoholic steatohepatitis. Catabasis Pharmaceuticals, Inc. has a pre-clinical joint research collaboration agreement with Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD. The company was founded in 2008 and is based in Cambridge, Massachusetts.